PROCEPT BioRobotics Corporation (PRCT)

Market Cap	1.31B -61.7%
Revenue (ttm)	308.05M +37.2%
Net Income	-95.57M
EPS	-1.72
Shares Out	56.39M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,116,599
Open	23.69
Previous Close	23.87
Day's Range	22.97 - 24.01
52-Week Range	19.35 - 66.85
Beta	0.93
Analysts	Buy
Price Target	35.44 (+52.3%)
Earnings Date	May 5, 2026

About PRCT

PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. The company also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hype...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Sep 15, 2021
• Employees: 888
• Stock Exchange: NASDAQ
• Ticker Symbol: PRCT
• Website: https://www.procept-biorobotics.com

Financial Performance

In 2025, PROCEPT BioRobotics's revenue was $308.05 million, an increase of 37.22% compared to the previous year's $224.50 million. Losses were -$95.57 million, 4.55% more than in 2024.

Analyst Summary

According to 11 analysts, the average rating for PRCT stock is "Buy." The 12-month stock price target is $35.44, which is an increase of 52.30% from the latest price.

Price Target

$35.44

(52.30% upside)

Analyst Consensus: Buy